Breaking News

Carlyle Pays $490M for 20% of Piramal Pharma

Will integrate Piramal Enterprises’ pharma businesses into its subsidiary Piramal Pharma Limited.

By: Contract Pharma

Contract Pharma Staff

Washington, D.C.-based investment firm The Carlyle Group has purchased a 20% stake in Piramal Pharma for $490 million.   Piramal Pharma, a subsidiary of Piramal Enterprises, includes Piramal Pharma Solutions, an end-to-end contract development and manufacturing (CDMO) business; Piramal Critical Care, a complex hospital generics business selling specialized products across over 100 countries; a consumer products division in India; and Piramal Enterprises investment in a joint venture with Allerga...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters